Meta AnalysisID 1562
在初始幽门螺杆菌根除治疗中添加铋剂的疗效：系统评价与Meta分析
CRD42022332462
To assess the effects of bismuth in the 1st line helicobacter pylori eradication
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1562
- Evidence Id
- 10120
- Core Evidence Id
- 10120
- Source Meta Analysis Id
- 1516
- Herb2 Meta Analysis Id
- HBMA001516
- Crd Id
- CRD42022332462
- Title
- Efficacy of adding bismuth to primary Helicobacter pylori eradication therapy : Systemic review and meta-analyses
- Review Question
- To assess the effects of bismuth in the 1st line helicobacter pylori eradication
- Study Type Included
- Randomized controlled trial
- Condition Being Studied
- Asia has the largest population of any continent and the highest incidence of gastric cancer in the world, making it very important in the context of Helicobacter pylori infection. According to current guidelines, standard triple therapy containing a proton pump inhibitor (PPI) and two antibiotics; amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ), is still the preferred first-line regimen for treatment of H. pylori infection. However, the efficacy of legacy triple regimens has been seriously challenged, and they are gradually becoming ineffective. Moreover, some regions in Asia show patterns of emerging antimicrobial resistance. Bismuth supplement has been known improving the efficacy of Helicobacter pylori eradication therapy by some studeis. Under the circumstances of antimicrobial resistance, we would study the efficacy of adding bismuth to primary Helicobacter pylori eradication therapy through systemic review and meta-analyses.
- Participant
- Patients with Helicobacter pylori infection were included. But who had experience of failure the 1st line eradication therapy of Helicobacter pylori were excluded.
- Animal
- Human Disease Modelled
- Intervention
- Adding bismuth supplement on 1st line helicobacter pylori eradication therapy
- Comparator Control
- Only the 1st line helicobacter pylori eradication therapy (without bismuth)
- Main Outcome
- Eradication rate
- Outcome Measure
- Additional Outcome
- Adverse event for eradication therapy
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans
- Contact
- Chung Hyun TAE [email protected]
- Organisational Affiliation
- Ewha Womans University College of Medicine
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- South Korea
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-05-13
- Registration Date
- 2022-05-24
- Anticipated Start Date
- 2022-05-14
- Anticipated Completion Date
- 2022-07-14
- Title Cn
- 在初始幽门螺杆菌根除治疗中添加铋剂的疗效：系统评价与Meta分析
- Title En
- Efficacy of adding bismuth to primary Helicobacter pylori eradication therapy : Systemic review and meta-analyses
- Bilingual Status
- complete